Journal: Molecules

Article Title: Susceptibility of Staphylococcus aureus to Anti-Inflammatory Drugs with a Focus on the Combinatory Effect of Celecoxib with Oxacillin In Vitro

doi: 10.3390/molecules29153665

Figure Lengend Snippet: In vitro growth-inhibitory activity of oxacillin and celecoxib combinations against S. aureus .

Article Snippet: The strongest synergistic interactions (FICI 0.087) were obtained against MRSA ATCC 33592 at a celecoxib concentration of 2 mg/L with a 19-fold oxacillin MIC reduction (from 512 to 26.888 mg/L).

Techniques: In Vitro, Activity Assay

Journal: ACS infectious diseases

Article Title: A Clerodane Diterpene from Callicarpa americana Resensitizes Methicillin-Resistant Staphylococcus aureus to ß-Lactam Antibiotics

doi: 10.1021/acsinfecdis.0c00307

Figure Lengend Snippet: Bioassay-guided fractionation of C. americana for synergy with oxacillin for growth inhibition of MRSA (LAC). Fractions with no FICI values (gray color) or no MIC values were screened for growth inhibition and synergy at single concentrations, but not investigated further. Yield for each fraction is calculated relative to parent; yield of crude extract 649 is relative to dry plant material.

Article Snippet: Against ATCC strains, compound 1 lowered the oxacillin MIC 16–512-fold at a concentration of 5 μg/mL; notably, 1 did not exhibit synergy with oxacillin against the oxacillin-susceptible S. aureus AR Bank #0470 and oxacillin-intermediate S. aureus AR Bank #0474. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 LAC and AR Bank Strains MIC Alone (μg/mL) MIC In Combination (μg/mL) FICI Compound 1 Oxacillin Compound 1 Oxacillin LAC 16 64 2 1 0.141 AR Bank #0470 16 4 8 0.625 0.65 AR Bank #0474 16 8 8 1 0.625 AR Bank #0480 16 32 4 1 0.283 ATCC Strains MIC Alone (μg/mL) Oxacillin MIC In Combination with 1 (μg/mL) Fold Reduction of Oxacillin MIC Oxacillin Conc. of 1 (μg/mL) Oxacillin ATCC BAA-1556 64 5 0.25 256 ATCC 43300 32 5 2 16 ATCC BAA-44 256 5 2 128 ATCC BAA-811 128 5 0.25 512 ATCC BAA-1770 32 5 2 16 ATCC 700789 128 5 2 64 ATCC 33591 128 5 2 64 ATCC BAA-1685 256 5 8 32 ATCC BAA-1753 256 5 0.5 512 Open in a separate window Interactions between 1 and oxacillin for growth inhibition of a panel of S. aureus strains.

Techniques: Bioassay, Fractionation, Inhibition

Journal: ACS infectious diseases

Article Title: A Clerodane Diterpene from Callicarpa americana Resensitizes Methicillin-Resistant Staphylococcus aureus to ß-Lactam Antibiotics

doi: 10.1021/acsinfecdis.0c00307

Figure Lengend Snippet: A) Time-kill assay of 1 and oxacillin against MRSA (LAC). The treatments displayed in this figure are ¼ MIC of 1 and ¼ MIC oxacillin alone and in combination, and DMSO, the vehicle control. B) Time-kill assay repeated with oxacillin concentrations at the susceptibility breakpoint (2 μg/mL).

Article Snippet: Against ATCC strains, compound 1 lowered the oxacillin MIC 16–512-fold at a concentration of 5 μg/mL; notably, 1 did not exhibit synergy with oxacillin against the oxacillin-susceptible S. aureus AR Bank #0470 and oxacillin-intermediate S. aureus AR Bank #0474. table ft1 table-wrap mode="anchored" t5 Table 1. caption a7 LAC and AR Bank Strains MIC Alone (μg/mL) MIC In Combination (μg/mL) FICI Compound 1 Oxacillin Compound 1 Oxacillin LAC 16 64 2 1 0.141 AR Bank #0470 16 4 8 0.625 0.65 AR Bank #0474 16 8 8 1 0.625 AR Bank #0480 16 32 4 1 0.283 ATCC Strains MIC Alone (μg/mL) Oxacillin MIC In Combination with 1 (μg/mL) Fold Reduction of Oxacillin MIC Oxacillin Conc. of 1 (μg/mL) Oxacillin ATCC BAA-1556 64 5 0.25 256 ATCC 43300 32 5 2 16 ATCC BAA-44 256 5 2 128 ATCC BAA-811 128 5 0.25 512 ATCC BAA-1770 32 5 2 16 ATCC 700789 128 5 2 64 ATCC 33591 128 5 2 64 ATCC BAA-1685 256 5 8 32 ATCC BAA-1753 256 5 0.5 512 Open in a separate window Interactions between 1 and oxacillin for growth inhibition of a panel of S. aureus strains.

Techniques: Time-Kill Assay, Control